Strengths and limitations
RECURRENCES, REMISSION
While there are several studies and reviews in the literature that have demonstrated the role of AZA in the management of GO, ours is the first multi-center study to investigate the effect of AZA, at specific doses, on the remission of GD. Another point of strengths was the large number of patients included, as well as the clinical homogeneity of the sample. Homogeneity of the sample ensures that all patients had similar characteristics. It can also improve the internal validity of the study and reduce the risk of confounding factors. Additionally, the study design included randomization of the study participants. Randomization is a key feature of clinical trials that helps to minimize bias and ensure that the treatment groups are comparable. However, a limitation of the study is that the follow-up period was only 12 months after the cessation of treatment, which may have been relatively short to evaluate long-term remission status, even though most GD recurrences tend to occur within the first 12 months after ATD withdrawal (